Stealth Biotherapeutics has developed a peptide that supports and stabilizes the inner mitochondrial membrane, improving ATP output and preserving cell viability. This compound is being tested in several rare diseases such as primary mitochondrial myopathy and Barth Syndrome, in addition to dry AMD. 

There are no therapies currently available on the market for this condition, which is 10 times more prevalent than wet AMD. Stealth is currently running a phase 2 clinical trial in this indication, in addition to its phase 3 trial in Barth.